New Guidelines Transform Diabetes Care During Pregnancy to Reduce Birth Defects
Joint clinical practice guidelines provide evidence-based recommendations for managing preexisting diabetes before, during, and after pregnancy.
Summary
The Endocrine Society and European Society of Endocrinology released comprehensive guidelines for managing preexisting diabetes during pregnancy. The guidelines emphasize preconception care, which can reduce congenital malformations by up to 42% when glycemic targets are achieved. Key recommendations include routine pregnancy intention screening, contraception counseling, discontinuing GLP-1 receptor agonists before conception, and using hybrid closed-loop insulin pumps for type 1 diabetes. The guidelines also address nutrition, glucose monitoring technology, and delivery timing to optimize outcomes for both mother and baby.
Detailed Summary
Preexisting diabetes affects approximately 1% of pregnancies worldwide and significantly increases risks of maternal and neonatal complications, including a 38-42% higher rate of congenital malformations. New joint clinical practice guidelines from the Endocrine Society and European Society of Endocrinology provide evidence-based recommendations to improve outcomes for individuals with diabetes before, during, and after pregnancy.
The guidelines emphasize the critical importance of preconception care, which remains underutilized despite compelling evidence showing it can dramatically reduce adverse outcomes. Only a minority of individuals with diabetes receive preconception care, yet achieving strict glycemic control before pregnancy can substantially reduce congenital malformations and other complications.
Key recommendations include routine screening for pregnancy intentions at every healthcare visit for reproductive-age individuals with diabetes, along with contraception counseling when pregnancy is not desired. For type 2 diabetes, the guidelines suggest discontinuing GLP-1 receptor agonists before conception rather than during early pregnancy, and recommend against routinely adding metformin to insulin therapy during pregnancy due to potential risks to fetal growth.
The guidelines address emerging diabetes technology, suggesting hybrid closed-loop insulin pumps for pregnant individuals with type 1 diabetes, which can improve glucose control and reduce dangerous low blood sugar episodes. For glucose monitoring, continuous glucose monitors may be used alongside traditional blood glucose monitoring, though specific pregnancy targets should be maintained rather than simplified 24-hour targets.
Regarding delivery timing, the guidelines recommend early delivery based on individual risk assessment rather than expectant management, typically before 38 weeks gestation. Postpartum endocrine care is emphasized to ensure continued diabetes management and preparation for future pregnancies. The recommendations acknowledge significant gaps in research, with most evidence rated as very low to low certainty, highlighting urgent needs for high-quality studies in this vulnerable population.
Key Findings
- Preconception care reduces congenital malformations by 38-42% in diabetes pregnancies
- Hybrid closed-loop insulin pumps improve glucose control in pregnant type 1 diabetics
- GLP-1 receptor agonists should be discontinued before conception, not during pregnancy
- Routine metformin addition to insulin therapy is not recommended during pregnancy
- Early delivery based on risk assessment is preferred over expectant management
Methodology
The guidelines were developed using GRADE methodology to assess evidence certainty and develop recommendations. A multidisciplinary panel reviewed systematic literature reviews addressing 10 prioritized clinical questions, with input from patient representatives and consideration of implementation factors.
Study Limitations
Most recommendations are based on very low to low certainty evidence, highlighting significant research gaps. Limited data exists on optimal nutrition management, obesity interventions, and ideal delivery timing in this population.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.